High-dose ruthenium-106 plaque therapy for circumscribed choroidal hemangioma: a retrospective study of 25 Chinese patients

作     者：Jing Li En-Zhong Jin Jian-Hong Liang 

作者机构：Department of OphthalmologyOphthalmology and Optometry CenterPeking University People’s Hospital and Beijing Key Laboratory of Diagnosis and Treatment of Retinal and Choroid DiseasesBeijing 100044China Department of OphthalmologyShaanxi Provincial People’s HospitalXi’an 710068Shaanxi ProvinceChina 

出 版 物：《International Journal of Ophthalmology(English edition)》 (国际眼科杂志（英文版）)

年 卷 期：2020年第13卷第3期

页      面：425-430页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：circumscribed choroidal hemangioma radiotherapy ruthenium-106 Chinese patients retrospective study 

摘      要：AIM:To evaluate the efficacy and safety of ruthenium-106(106Ru)plaque radiotherapy at a dose(50 Gy)higher than recommended(29-50 Gy)for treatment of circumscribed choroidal hemangioma(CCH)in Chinese ***:This retrospective study included 25symptomatic CCH patients undergoing 106Ru plaque brachytherapy involving 25 eyes between January 2005and August *** examination was performed at the baseline and at each post-treatment follow-up visit,using best-corrected visual acuity(BCVA),dilated fundus examination,and B-scan *** primary efficacy outcome measures included the changes in BCVA and hemangioma dimensions at the last followup visit from the ***:The mean follow-up duration was 28.0±26.6(range,12-110)*** the hemangiomas were located in the posterior pole except for two involving the *** mean apex dose of 106Ru plaque radiotherapy was84.4±19.7 *** mean BCVA improved from 41.4±29.3(0-97)at the baseline to 53.0±33.8(0-97)ETDRS letters at the last visit(P=0.01).The mean hemangioma height declined from 3.98±0.88(2.40-5.50)mm to 0.84±1.63(0-6.47)mm(P≤0.001),and the greatest linear diameter(GLD)reduced from 9.36±2.23(6.80-15.00)to 7.40±2.45(0-13.00)mm(P≤0.001).Hemangioma size increased in one(4%)eye with a worsened vision,and subretinal fluid completely resolved in all but one patient(4%).Radiationrelated retinopathy was observed in two patients at posttreatment 9 and 11mo,***:106Ru plaque brachytherapy at a dose(50 Gy)higher than recommended(29-50 Gy)is an effective treatment regimen for symptomatic CCH associated with significantly improved visual acuity and a favorable safety profile in Chinese patients.